Finished product reference
Diclofenac Sodium
Tablet, Delayed Release · Oral · 50 mg
- List code
- 2041
WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction, and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. [ see Warnings and Precautions ].
What it is and how it works
Mechanism of Action Diclofenac has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of diclofenac sodium topical solution, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Diclofenac is a potent inhibitor of prostaglandin synthesis in vitro . Diclofenac concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation.
Indications
Diclofenac sodium topical solution is indicated for the treatment of the pain of osteoarthritis of the knee(s). Diclofenac sodium topical solution is a nonsteroidal anti-inflammatory drug indicated for the treatment of the pain of osteoarthritis of the knee(s).
Dosage and administration (summary)
Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals. The recommended dose is 2 pump actuations on each painful knee, 2 times a day. Apply diclofenac sodium topical solution, to clean, dry skin. Dispense 40 mg (2 pump actuations) directly onto the knee or first into the hand and then onto the knee. Spread evenly around front, back and sides of the knee. Wash hands completely after administering the product. Wait until the area is completely dry before covering with clothing or applying sunscreen, insect repellent, cosmetics, topical medications, or other substances.
Contraindications
Diclofenac sodium topical solution is contraindicated in the following patients: Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product [ see Warnings and Precautions ( 5.7 , 5.9 ) ] History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs.
Warnings and precautions
Hepatotoxicity : Inform patients of warning signs and symptoms of hepatotoxicity. Discontinue if abnormal liver tests persist or worsen or if clinical signs and symptoms of liver disease develop Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs.Monitor blood pressure ( 5.4 , 7 ) Heart Failure and Edema : Avoid use of diclofenac sodium topical solution in patients with severe heart failure unless benefits are expected to outweigh risk of worsening heart failure Renal Toxicity : Monitor renal function in patients wit…
Pregnancy
Pregnancy Risk Summary Use of NSAIDs, including diclofenac sodium topical solution, can cause premature closure of the fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment.
Storage and supply
Diclofenac sodium topical solution USP, 2% w/w, is supplied as a clear, colorless to faintly pink or orange solution containing 20 mg of diclofenac sodium per gram of solution, in a white polypropylene-dose pump bottle with a clear cap. Each pump actuation delivers 20 mg of diclofenac sodium in 1 gram of solution.
Source: Diclofenac Sodium (Diclofenac Sodium) — US FDA prescribing information, 2025-01-17, DailyMed. Summarised and shortened; the full label governs. Iranian registration, indications and labelling may differ.
Other presentations of the same active ingredient
- Plaster · Topical · 120 mg22637
- Capsule, Liquid Filled · Oral · 25 mg51105
- Powder, for Solution · Oral · 50 mg53665
- Tablet · Oral · 50 mg15917
- Capsule, Extended Release · Oral · 100 mg1993
- Gel · Topical · 3 % · 60 g53380
- Injection · Parenteral · 25 mg/1mL · 3 mL425
- Solution · Topical · 2 % · 60 mL52705
- Solution, Drops · Ophthalmic · 0.1 % · 5 mL1847
- Suppository · Rectal · 100 mg427
- Suppository · Rectal · 50 mg428
- Tablet, Delayed Release · Oral · 25 mg424
- Tablet, Extended Release · Oral · 100 mg1464
- Tablet, Extended Release · Oral · 150 mg53050
- Tablet, Extended Release · Oral · 75 mg19930
Reference information for professional sourcing and registration enquiries, not medical advice or a promotion. Drug information is condensed from US FDA prescribing information (public domain, via openFDA and DailyMed) and does not replace the product’s approved labelling in Iran. Availability, origin and documentation are confirmed per enquiry.
Tell us the quantity, the market and the timing.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.